117 related articles for article (PubMed ID: 10930114)
1. Aberrant expression of TSG101 in Taiwan Chinese breast cancer.
Lo YF; Chen TC; Chen SC; Chao CC
Breast Cancer Res Treat; 2000 Apr; 60(3):259-66. PubMed ID: 10930114
[TBL] [Abstract][Full Text] [Related]
2. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
Carney ME; Maxwell GL; Lancaster JM; Gumbs C; Marks J; Berchuck A; Futreal PA
J Soc Gynecol Investig; 1998; 5(5):281-5. PubMed ID: 9773405
[TBL] [Abstract][Full Text] [Related]
3. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
[TBL] [Abstract][Full Text] [Related]
4. Evidence that TSG101 aberrant transcripts are PCR artifacts.
Hampl M; Hampl J; Plaschke J; Fitze G; Schackert G; Saeger HD; Schackert HK
Biochem Biophys Res Commun; 1998 Jul; 248(3):753-60. PubMed ID: 9704000
[TBL] [Abstract][Full Text] [Related]
5. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
6. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
7. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer.
Li L; Li X; Francke U; Cohen SN
Cell; 1997 Jan; 88(1):143-54. PubMed ID: 9019400
[TBL] [Abstract][Full Text] [Related]
8. Identification of cellular TSG101 protein in multiple human breast cancer cell lines.
Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH
Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081
[TBL] [Abstract][Full Text] [Related]
9. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
Hosokawa Y; Nagai E; Seto M
J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
[TBL] [Abstract][Full Text] [Related]
10. Absence of TSG101 transcript abnormalities in human cancers.
Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
[TBL] [Abstract][Full Text] [Related]
11. Aberrant TSG101 transcripts in acute myeloid leukaemia.
Lin PM; Liu TC; Chang JG; Chen TP; Lin SF
Br J Haematol; 1998 Aug; 102(3):753-8. PubMed ID: 9722303
[TBL] [Abstract][Full Text] [Related]
12. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.
Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT
Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421
[TBL] [Abstract][Full Text] [Related]
14. Frequent abnormalities of TSG101 transcripts in human prostate cancer.
Sun Z; Pan J; Bubley G; Balk SP
Oncogene; 1997 Dec; 15(25):3121-5. PubMed ID: 9444960
[TBL] [Abstract][Full Text] [Related]
15. Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines.
Ferrer M; López-Borges S; Lazo PA
Oncogene; 1999 Apr; 18(13):2253-9. PubMed ID: 10327071
[TBL] [Abstract][Full Text] [Related]
16. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation.
Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU
Oncogene; 2007 Aug; 26(40):5950-9. PubMed ID: 17369844
[TBL] [Abstract][Full Text] [Related]
17. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.
Turpin E; Dalle B; de Roquancourt A; Plassa LF; Marty M; Janin A; Beuzard Y; de Thé H
Oncogene; 1999 Dec; 18(54):7834-7. PubMed ID: 10618725
[TBL] [Abstract][Full Text] [Related]
18. Role of TSG101 in uterine cervix cancer.
O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY
Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297
[TBL] [Abstract][Full Text] [Related]
19. TSGΔ154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal degradation.
Chua HH; Huang CS; Weng PL; Yeh TH
Oncotarget; 2016 Feb; 7(7):8240-52. PubMed ID: 26811492
[TBL] [Abstract][Full Text] [Related]
20. Truncated TSG101 transcripts are present in peripheral blood from both familial breast cancer patients and controls.
Xu CF; Greenman J; Solomon E
Eur J Cancer; 1998 Jun; 34(7):1077-80. PubMed ID: 9849457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
